163 related articles for article (PubMed ID: 35137332)
21. Primary Central Nervous System Lymphoma: Clinical Characteristics, Treatment Options and Therapeutic Outcome in 36 Patients. A Single Center Experience.
Zektser M; Rabinovich A; Grinbaum U; Porges T; Gozlan A; Gourevitch A; Al-Athamen K; Barrett O; Peles I; Kaisman-Elbaz T; Levi E
Isr Med Assoc J; 2022 Oct; 24(10):654-660. PubMed ID: 36309861
[TBL] [Abstract][Full Text] [Related]
22. High-dose methotrexate-based regimens and post-remission consolidation for treatment of newly diagnosed primary CNS lymphoma: meta-analysis of clinical trials.
Yu J; Du H; Ye X; Zhang L; Xiao H
Sci Rep; 2021 Jan; 11(1):2125. PubMed ID: 33483528
[TBL] [Abstract][Full Text] [Related]
23. The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma.
Opat S; Tedeschi A; Linton K; McKay P; Hu B; Chan H; Jin J; Sobieraj-Teague M; Zinzani PL; Coleman M; Thieblemont C; Browett P; Ke X; Sun M; Marcus R; Portell CA; Ardeshna K; Bijou F; Walker P; Hawkes EA; Mapp S; Ho SJ; Talaulikar D; Zhou KS; Co M; Li X; Zhou W; Cappellini M; Tankersley C; Huang J; Trotman J
Clin Cancer Res; 2021 Dec; 27(23):6323-6332. PubMed ID: 34526366
[TBL] [Abstract][Full Text] [Related]
24. Salvage radiotherapy in patients with recurrent or refractory primary or secondary central nervous system lymphoma after methotrexate-based chemotherapy.
Khimani NB; Ng AK; Chen YH; Catalano P; Silver B; Mauch PM
Ann Oncol; 2011 Apr; 22(4):979-984. PubMed ID: 20935059
[TBL] [Abstract][Full Text] [Related]
25. Bruton's tyrosine kinase inhibitors in Refractory or Relapsing Primary Central Nervous System Lymphoma: A meta-analysis and systematic review.
Guo HP; Dang XL; Kang L; Liu C; Liu XW
World Neurosurg; 2024 Apr; ():. PubMed ID: 38641241
[TBL] [Abstract][Full Text] [Related]
26. Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma.
Tun HW; Johnston PB; DeAngelis LM; Atherton PJ; Pederson LD; Koenig PA; Reeder CB; Omuro AMP; Schiff D; O'Neill B; Pulido J; Jaeckle KA; Grommes C; Witzig TE
Blood; 2018 Nov; 132(21):2240-2248. PubMed ID: 30262659
[TBL] [Abstract][Full Text] [Related]
27. Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
Telford C; Kabadi SM; Abhyankar S; Song J; Signorovitch J; Zhao J; Yao Z
Clin Ther; 2019 Nov; 41(11):2357-2379.e1. PubMed ID: 31699438
[TBL] [Abstract][Full Text] [Related]
28. [Programmed cell death-1 inhibitor combined with rituximab in refractory or relapsed diffuse large B-cell lymphoma: a preliminary efficacy and safety analysis].
Qin Y; Zhao FY; Zhou Y; Jiang SY; Yang S; Shi YK
Zhonghua Zhong Liu Za Zhi; 2020 Dec; 42(12):1034-1039. PubMed ID: 33342160
[No Abstract] [Full Text] [Related]
29. [Efficacy and survival analysis of DICE regimen for 97 patients with relapsed or refractory Non-Hodgkin's lymphoma].
Ping LY; Song YQ; Zheng W; Wang XP; Xie Y; Lin NJ; Tu MF; Ying ZT; Liu WP; Zhang C; Deng LJ; Zhu J
Zhonghua Xue Ye Xue Za Zhi; 2016 Sep; 37(9):790-794. PubMed ID: 27719723
[TBL] [Abstract][Full Text] [Related]
30. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202).
Rubenstein JL; Hsi ED; Johnson JL; Jung SH; Nakashima MO; Grant B; Cheson BD; Kaplan LD
J Clin Oncol; 2013 Sep; 31(25):3061-8. PubMed ID: 23569323
[TBL] [Abstract][Full Text] [Related]
31. Clinical Efficacy of Bendamustine Plus Rituximab (BR) for B-cell Relevant Indolent Non-Hodgkin's Lymphoma and Role of
Zhang Y; He D; He J; Huang W; Yang Y; Cai Z; Zhao Y
Comput Math Methods Med; 2022; 2022():1080879. PubMed ID: 35096126
[TBL] [Abstract][Full Text] [Related]
32. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
[TBL] [Abstract][Full Text] [Related]
33. Treatment strategies in primary vitreoretinal lymphoma: a 17-center European collaborative study.
Riemens A; Bromberg J; Touitou V; Sobolewska B; Missotten T; Baarsma S; Hoyng C; Cordero-Coma M; Tomkins-Netzer O; Rozalski A; Tugal-Tutkun I; Guex-Crosier Y; Los LI; Bollemeijer JG; Nolan A; Pawade J; Willermain F; Bodaghi B; ten Dam-van Loon N; Dick A; Zierhut M; Lightman S; Mackensen F; Moulin A; Erckens R; Wensing B; le Hoang P; Lokhorst H; Rothova A
JAMA Ophthalmol; 2015 Feb; 133(2):191-7. PubMed ID: 25412269
[TBL] [Abstract][Full Text] [Related]
34. First-line high-dose therapy and autologous blood stem cell transplantation in patients with primary central nervous system non-Hodgkin lymphomas-a single-centre experience in 61 patients.
Brezina T; von Dewitz H; Schroeder T; Ullrich S; Nachtkamp K; Reifenberger G; Malzkorn B; Sabel M; Haas R; Kobbe G
Ann Hematol; 2022 Mar; 101(3):607-616. PubMed ID: 34982196
[TBL] [Abstract][Full Text] [Related]
35. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
36. Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: A real-world experience of off-label ibrutinib use.
Chen F; Pang D; Guo H; Ou Q; Wu X; Jiang X; Wei X; Liu S; Huang L; Liang Z; Zhou D; Li W
Cancer Med; 2020 Nov; 9(22):8676-8684. PubMed ID: 33068336
[TBL] [Abstract][Full Text] [Related]
37. [New Advances in the Treatment of Primary Central Nervous System Lymphoma--Review].
Hu BN; Yang X; Yuan YP; Chen YJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):633-637. PubMed ID: 33812443
[TBL] [Abstract][Full Text] [Related]
38. Effect and Safety of Orelabrutinib and Lenalidomide Plus R-mini CDOP in Relapsed/Refractory Aggressive B-cell Non-Hodgkin Lymphoma.
Shang Y; Zhao H; Li D
Turk J Haematol; 2023 Dec; 40(4):284-285. PubMed ID: 37656047
[No Abstract] [Full Text] [Related]
39. Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.
Grommes C; Tang SS; Wolfe J; Kaley TJ; Daras M; Pentsova EI; Piotrowski AF; Stone J; Lin A; Nolan CP; Manne M; Codega P; Campos C; Viale A; Thomas AA; Berger MF; Hatzoglou V; Reiner AS; Panageas KS; DeAngelis LM; Mellinghoff IK
Blood; 2019 Jan; 133(5):436-445. PubMed ID: 30567753
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenström's macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study.
Cao XX; Jin J; Fu CC; Yi SH; Zhao WL; Sun ZM; Yang W; Li DJ; Cui GH; Hu JD; Liu T; Song YP; Xu B; Zhu ZM; Xu W; Zhang MZ; Tian YM; Zhang B; Zhao RB; Zhou DB
EClinicalMedicine; 2022 Oct; 52():101682. PubMed ID: 36313145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
